Chembio Diagnostics, Inc. (Chembio), and its wholly owned subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's main products presently commercially available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format, and a barrel format. Its Dual Path Platform (DPP) HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. Additionally, Chembio's product pipeline includes a multiplex test that detects P24 HIV antigen, as well as HIV 1/2 antibodies, and a rapid test for the detection of Hepatitis-C antibodies.